Holen Sie sich die Stockscreener-App
1.71
6.21%
0.10
Vorhandelsmarkt:
1.66
-0.05
-2.92%
Schlusskurs vom Vortag:
$1.61
Offen:
$1.63
24-Stunden-Volumen:
1.63M
Relative Volume:
0.52
Marktkapitalisierung:
$483.59M
Einnahmen:
$53.43M
Nettoeinkommen (Verlust:
$-52.49M
KGV:
-4.7646
EPS:
-0.3589
Netto-Cashflow:
$-58.29M
1W Leistung:
+26.67%
1M Leistung:
-1.72%
6M Leistung:
-2.29%
1J Leistung:
+232.68%
1-Tages-Spanne:
$1.62
$1.735
1-Wochen-Bereich:
$1.39
$1.80
52-Wochen-Spanne:
$0.4613
$3.0699
Invivyd Inc Stock (IVVD) Company Profile
Firmenname
Invivyd Inc
Sektor
Branche
Telefon
(781) 819-0080
Adresse
209 CHURCH STREET, NEW HAVEN
Compare IVVD vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
1.71 | 455.31M | 53.43M | -52.49M | -58.29M | -0.3589 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-22 | Eingeleitet | BTIG Research | Buy |
| 2025-11-25 | Herabstufung | D. Boral Capital | Buy → Hold |
| 2025-10-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-04-05 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-03-26 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-19 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-05-01 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Invivyd Inc Aktie (IVVD) Neueste Nachrichten
Invivyd rises after update from late-stage trial for COVID therapy - MSN
Invivyd stock surges as FDA alignment boosts COVID-19 program - MSN
Aug Reactions: What are Invivyd Incs technical support levelsLayoff News & Expert-Curated Trade Recommendations - baoquankhu1.vn
Invivyd: Why The Trial Upsizing Isn't The Green Light Bulls Think It Is (NASDAQ:IVVD) - Seeking Alpha
Authentic virus research in labs faces adaptation hurdles, Invivyd, Inc. asserts - Traders Union
Invivyd unveils measles monoclonal antibody candidate VMS-063 - BioWorld News
H.C. Wainwright reiterates Invivyd stock rating on measles program By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Invivyd stock rating on measles program - Investing.com
Invivyd upsizes COVID-19 trial, targets measles antibody By Investing.com - Investing.com Australia
Invivyd, Inc. (IVVD) Discusses Progress in REVOLUTION Clinical Program and Advancement of Measles Monoclonal Antibody CandidateSlideshow (NASDAQ:IVVD) 2026-04-09 - Seeking Alpha
Invivyd Updates VYD2311 REVOLUTION Trials, Modestly Upsizes Study, Unveils Measles mAb VMS-063 - MarketBeat
Invivyd reveals plans to test an antibody drug against measles - BioPharma Dive
Invivyd posts update from late-stage COVID trial (IVVD:NASDAQ) - Seeking Alpha
Invivyd stock surges 25% on COVID-19 trial progress By Investing.com - Investing.com Australia
Invivyd stock surges 25% on COVID-19 trial progress - Investing.com
Invivyd Stock Surges As FDA Alignment Boosts COVID-19 ProgramInvivyd (NASDAQ:IVVD) - Benzinga
Invivyd Advances COVID-19 and Measles Monoclonal Antibody Programs With Phase 3 Updates and New VMS063 Candidate for Measles Prevention and Treatment 1 - Minichart
Invivyd Advances COVID-19 Program and Launches Measles Antibody - TipRanks
Invivyd upsizes DECLARATION Phase 3, delays topline to Q3 2026; advances measles mAb VMS063 toward IND - TradingView
Invivyd upsizes COVID-19 trial, targets measles antibody - Investing.com
Invivyd (IVVD) expands VYD2311 Phase 3 and pushes potent measles antibody VMS063 toward clinic - Stock Titan
Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles - The Manila Times
Invivyd, Inc. outlines antibody response as critical for immune defense actions - Traders Union
Surprises Report: What makes Invivyd Inc stock attractive todayQuarterly Portfolio Review & Low Risk Entry Point Guides - baoquankhu1.vn
Invivyd Launches "Antibodies for Any Body" in Partnership with World Champion Skier Lindsey Vonn to Inspire Actions that Help Support Immune Health - Bitget
Invivyd Launches 'Antibodies for Any Body” in Partnership with World Champion Skier Lindsey Vonn to Inspire Actions that Help Support Immune Health - The Manila Times
Lindsey Vonn joins Invivyd's antibody education campaign - Stock Titan
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
Invivyd, Inc. (IVVD) Reports Q3 Loss, Lags Revenue Estimates - MSN
Invivyd (NASDAQ: IVVD) plans 2026 virtual meeting and auditor vote - Stock Titan
16 new Invivyd hires get stock options at $1.33 exercise price - Stock Titan
IVVD Technical Analysis & Stock Price Forecast - Intellectia AI
Invivyd, Inc. (NASDAQ:IVVD) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Invivyd Inc. (IVVD) Stock Price Quote Today & Current Price Chart - Capital.com
Joel Greenblatt's Invivyd Inc(IVVD) Holding History - gurufocus.com
Invivyd Announces Presentation at the World Vaccine Congress Washington - The Manila Times
At vaccine congress, Invivyd says antibody drugs can track viral shifts - Stock Titan
Investment Recap: What makes Invivyd Inc stock attractive today2026 Short Interest & High Yield Equity Trading Tips - baoquankhu1.vn
Exploring Three High Growth Tech Stocks In The US Market - simplywall.st
Analysis Recap: What is the target price for Invivyd Inc stockTrade Signal Summary & Daily Stock Trend Watchlist - baoquankhu1.vn
HC Wainwright & Co. Maintains Invivyd (IVVD) Buy Recommendation - MSN
Insider Buy: How liquid is Invivyd Inc stock2026 Breakouts & Breakdowns & Weekly Top Performers Watchlists - baoquankhu1.vn
Finanzdaten der Invivyd Inc-Aktie (IVVD)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):